Call the shots: vaccine cuts imperil global health

Call the shots: vaccine cuts imperil global h...

Up next

The third Gulf war: one week on

After a momentous week, our editors reflect on how uncertainty about the goals of the war in Iran will affect its course. Iran’s retaliation has been fierce and wide ranging. How long can Gulf stocks of missile interceptors last? And our obituaries editor looks back at the life o ...  Show more

Spars and strikes: Who backs Iran war?

As America continues to batter Iran, what are the domestic implications of the war for Donald Trump? The widening conflict has prompted some European countries to deploy defensive forces. France has also announced a bigger shift in policy: to bolster its nuclear arsenal. And the ...  Show more

Recommended Episodes

Call the shots: vaccine cuts imperil global health
The Intelligence from The Economist

America’s health secretary, RFK Jr, is known for his opposition to vaccines, particularly mRNA jabs, that have the potential to treat a large swathe of diseases. Slashing funding will have long term implications beyond America. Our correspondent visits Britain’s biggest and newes ...  Show more

The human strain: can mpox be contained?
The Intelligence from The Economist

Mpox is spreading fast across Africa, yet public information campaigns are scant and vaccines in short supply. Is a new pandemic in the offing? Strategists are pondering a new potential threat from Russia: the possibility that it could detonate a <a href="https://www.economist ...

  Show more

Rio brand: why Brazil is courting China
The Intelligence from The Economist

Trade ties between <a href="https://www.economist.com/the-americas/2024/11/17/brazil-courts-china-as-its-musk-feud-erupts-again?utm_campaign=a.io&utm_medium=audio.podcast.np&utm_source=theintelligence&utm_content=discovery.content.anonymous.tr_shownotes_na-na_article&utm_term= ...

  Show more

Wary pharma: AstraZeneca sours on UK
The Intelligence from The Economist

Pharmaceutical giant AstraZeneca has paused a £200m investment in Britain and could move its primary listing to America. Can the UK maintain its status as a “life-science superpower”? Why autonomous air wings are the future of war in the sky. And how scientists in the Caribbean a ...  Show more